Oral desensitization to rifampin and ethambutol in mycobacterial disease

Jonathan Matz, Larry C. Borish, John M. Routes, Lanny J. Rosenwasser

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


The incidence of disease caused by Mycobacterium tuberculosis (including drug-resistant strains) and M. avium complex (MAC) is increasing. Hypersensitivity reactions to antimycobacterial agents are relatively uncommon, but when they occur they may result in cessation of therapeutic medications. We report our experience with rapid oral desensitization to ethambutol and rifampin in a group of 10 patients with mycobacterial disease who had experienced cutaneous hypersensitivity reactions to these drugs. An adaptation of the rapid oral desensitization protocol for penicillin was used, with the dosing intervals increased to account for the different kinetics of these drugs. Adverse reactions were few and easily treated without necessitating cessation of therapy. We conclude that oral desensitization to rifampin and ethambutol by our protocol is safe and effective, allowing these patients to proceed with an optimal antimycobacterial regimen.

Original languageEnglish (US)
Pages (from-to)815-817
Number of pages3
JournalAmerican journal of respiratory and critical care medicine
Issue number3 I
StatePublished - Mar 1994
Externally publishedYes

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Oral desensitization to rifampin and ethambutol in mycobacterial disease'. Together they form a unique fingerprint.

Cite this